| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 465.8 | 437.0 | 321.5 |
| Other income | 3.1 | 1.7 | 6.4 |
| Total income | 468.9 | 438.7 | 327.9 |
| Profit before exceptional items & tax | 98.1 | 95.4 | 49.6 |
| Exceptional items | 0.0 | 25.0 | 0.0 |
| Profit before tax | 98.1 | 120.4 | 49.6 |
| Net profit | 100.9 | 107.8 | 46.9 |
| Operating margin | 20.9% | 27.4% | 15.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +115.10% |
|---|---|
| Net profit, quarter on quarter | -6.40% |
| Revenue, year on year | +44.90% |
| Operating profit, year on year | +119.90% |
| Operating profit, quarter on quarter | +1.40% |
BSE results filing, NSE: SHILPAMED. Figures extracted from the filing.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹1,013.45
- Market cap
- ₹19,821 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 66.7×Sector 50.4×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 11.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Share Pledge
The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.
Shilpa Medicare Other Announcement
Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.
Shilpa Medicare Business Update
Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.
Shilpa Medicare Regulatory Approval
Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.
Shilpa Medicare Annual General Meeting
Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.
Shilpa Medicare Insolvency Petition
NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.
- Value
- ₹2.18 Cr